Ratings by Citizens (Jason Butler)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/6/2026 | GH Research PLC | GHRS | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/6/2026 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/27/2026 | argenx SE | ARGX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/26/2026 | Ironwood Pharmaceuticals | IRWD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/26/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/25/2026 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/23/2026 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/3/2026 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/8/2026 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/8/2026 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/6/2026 | GH Research PLC | GHRS | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/5/2026 | Ironwood Pharmaceuticals | IRWD | Upgrade | Market Outperform (Market Perform) |
3.37 (3.50) |
3.86% | Details | |
| 12/22/2025 | Cytokinetics | CYTK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/18/2025 | Nasus Pharma Ltd | NSRX | New Coverage | Market Outperform (N/A) |
6.80 (4.86) |
-28.53% | Details | |
| 12/16/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/8/2025 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/5/2025 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 12/1/2025 | Prothena Corp | PRTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/25/2025 | Achieve Life Sciences | ACHV | New Coverage | Market Outperform (N/A) |
3.96 (4.27) |
7.83% | Details | |
| 11/7/2025 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/4/2025 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 11/4/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/31/2025 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/29/2025 | Rezolute | RZLT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/9/2025 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/6/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/1/2025 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/25/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/23/2025 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/23/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/19/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/18/2025 | Rezolute | RZLT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/8/2025 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/2/2025 | Prothena Corp | PRTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/13/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/7/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/6/2025 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 8/5/2025 | Prothena Corp | PRTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 7/24/2025 | GH Research PLC | GHRS | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 7/23/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 7/18/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 7/16/2025 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 7/14/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 7/8/2025 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/26/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/24/2025 | GH Research PLC | GHRS | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/3/2025 | Rapport Therapeutics | RAPP | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/27/2025 | Prothena Corp | PRTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/22/2025 | Vigil Neuroscience Inc | VIGL | Downgrade | Market Perform (Market Outperform) |
2.48 (8.05) |
224.6% | Details | |
| 5/14/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/14/2025 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/14/2025 | argenx SE | ARGX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/14/2025 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/12/2025 | Athira Pharma | ATHA | Maintain | Market Perform (Market Perform) |
|
Details | ||
| 5/9/2025 | Prothena Corp | PRTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/7/2025 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/2/2025 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/30/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/15/2025 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/14/2025 | Ironwood Pharmaceuticals | IRWD | Downgrade | Market Perform (Market Outperform) |
0.95 (3.37) |
254.74% | Details | |
| 4/10/2025 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 4/8/2025 | Rapport Therapeutics | RAPP | New Coverage | Market Outperform (N/A) |
9.51 (30.24) |
217.98% | Details | |
| 4/3/2025 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/20/2025 | Paragon Shipping Inc. | PRGN | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/18/2025 | Abivax | ABVX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/12/2025 | Zevra Therapeutics, Inc. | ZVRA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/6/2025 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/28/2025 | argenx SE | ARGX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/19/2025 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/18/2025 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/13/2025 | Rezolute | RZLT | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/7/2025 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/30/2025 | Ironwood Pharmaceuticals | IRWD | Maintain | Market Perform (N/A) |
|
Details | ||
| 1/14/2025 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/4/2024 | Abivax | ABVX | New Coverage | Market Outperform (N/A) |
8.48 (109.33) |
1189.27% | Details | |
| 11/1/2024 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/1/2024 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/9/2024 | Vigil Neuroscience Inc | VIGL | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/8/2024 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/1/2024 | Ironwood Pharmaceuticals | IRWD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 9/24/2024 | Zevra Therapeutics, Inc. | ZVRA | New Coverage | Market Outperform (N/A) |
8.06 (8.98) |
11.41% | Details | |
| 9/4/2024 | Athira Pharma | ATHA | Downgrade | Market Perform (Market Outperform) |
3.09 (6.75) |
118.45% | Details | |
| 5/10/2024 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/9/2024 | Prothena Corp | PRTA | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/9/2024 | Cytokinetics | CYTK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/8/2024 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/15/2024 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/12/2024 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/1/2024 | GH Research PLC | GHRS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/1/2024 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/28/2024 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/16/2024 | Prothena Corp | PRTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/22/2023 | Karuna Therapeutics Inc. | KRTX | Downgrade | Market Perform (Market Outperform) |
215.19 (329.83) |
53.27% | Details | |
| 11/14/2023 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/14/2023 | Rezolute | RZLT | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/18/2023 | Vigil Neuroscience Inc | VIGL | New Coverage | Market Outperform (N/A) |
6.17 (2.48) |
-59.81% | Details | |
| 9/28/2023 | Ironwood Pharmaceuticals | IRWD | New Coverage | Market Outperform (N/A) |
9.40 (3.50) |
-62.77% | Details | |
| 8/11/2023 | Athira Pharma | ATHA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/9/2023 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/4/2023 | Prothena Corp | PRTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/14/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/12/2023 | GH Research PLC | GHRS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/10/2023 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/9/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/5/2023 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/3/2023 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/28/2023 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/22/2023 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/23/2022 | Applied Molecular Transport | AMTI | Downgrade | Market Perform (Market Outperform) |
1.06 (0.26) |
-75.47% | Details | |
| 12/14/2022 | Cytokinetics | CYTK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/15/2022 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/9/2022 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/4/2022 | Prothena Corp | PRTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/28/2022 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/17/2022 | Athira Pharma | ATHA | Upgrade | Market Outperform (Market Perform) |
3.21 (3.09) |
-3.74% | Details | |
| 10/17/2022 | Minerva Neurosciences | NERV | Downgrade | Market Perform (Market Outperform) |
13.43 (6.01) |
-55.25% | Details | |
| 10/3/2022 | Cytokinetics | CYTK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/28/2022 | Prothena Corp | PRTA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/19/2022 | Quoin Pharmaceuticals | QNRX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/15/2022 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/15/2022 | PLx Pharma | PLXP | Downgrade | Market Perform (Market Outperform) |
2.59 (0.09) |
-96.53% | Details | |
| 8/10/2022 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/5/2022 | Cytokinetics | CYTK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/3/2022 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/29/2022 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/28/2022 | Karuna Therapeutics Inc. | KRTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/23/2022 | Athira Pharma | ATHA | Downgrade | Market Perform (Market Outperform) |
8.45 (3.21) |
-62.01% | Details | |
| 5/19/2022 | Applied Molecular Transport | AMTI | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/11/2022 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/6/2022 | Rezolute | RZLT | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/11/2022 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/1/2022 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/25/2022 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/27/2022 | Cortexyme Inc. | CRTX | Downgrade | Market Perform (Market Outperform) |
9.06 (1.95) |
-78.48% | Details | |
| 12/21/2021 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/21/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/20/2021 | Cytokinetics | CYTK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/15/2021 | Quoin Pharmaceuticals | QNRX | New Coverage | Market Outperform (N/A) |
3.27 (8.67) |
165.14% | Details | |
| 12/14/2021 | Arena Pharma | ARNA | Downgrade | Market Perform (Market Outperform) |
49.94 (99.98) |
100.2% | Details | |
| 12/7/2021 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/15/2021 | Rezolute | RZLT | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/5/2021 | Viridian Therapeutic | VRDN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/4/2021 | Karuna Therapeutics Inc. | KRTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/3/2021 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/24/2021 | GH Research PLC | GHRS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/20/2021 | PLx Pharma | PLXP | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/20/2021 | GH Research PLC | GHRS | New Coverage | Market Outperform (N/A) |
17.50 (15.93) |
-8.97% | Details | |
| 5/14/2021 | CorMedix | CRMD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/14/2021 | Applied Molecular Transport | AMTI | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/11/2021 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/7/2021 | Cytokinetics | CYTK | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/6/2021 | Baudax Bio Inc. | BXRX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 5/5/2021 | Esperion Therapeutics | ESPR | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/31/2021 | CorMedix | CRMD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/17/2021 | Applied Molecular Transport | AMTI | New Coverage | Market Outperform (N/A) |
72.00 (0.26) |
-99.64% | Details | |
| 3/5/2021 | argenx SE | ARGX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 3/3/2021 | Zogenix, Inc. | ZGNX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/2/2021 | CorMedix | CRMD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/26/2021 | Zogenix, Inc. | ZGNX | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/26/2021 | Adamas Pharmaceuticals | ADMS | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/25/2021 | Karuna Therapeutics Inc. | KRTX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/24/2021 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 2/19/2021 | CorMedix | CRMD | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 1/7/2021 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/9/2020 | Marinus Pharmaceuticals | MRNS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/17/2020 | PLx Pharma | PLXP | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/10/2020 | Neos Therapeutics | NEOS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/2/2020 | Axovant Gene Therapies | AXGT | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/14/2020 | Rezolute | RZLT | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/5/2020 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/29/2020 | CorMedix | CRMD | New Coverage | Market Outperform (N/A) |
5.20 (6.46) |
24.23% | Details | |
| 9/25/2020 | Marinus Pharmaceuticals | MRNS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/11/2020 | Neos Therapeutics | NEOS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/31/2020 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/21/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/11/2020 | Axovant Gene Therapies | AXGT | Maintain | Market Outperform (N/A) |
|
Details | ||
| 5/18/2020 | PLx Pharma | PLXP | New Coverage | Market Outperform (N/A) |
2.60 (0.09) |
-96.54% | Details | |
| 5/15/2020 | Baudax Bio Inc. | BXRX | New Coverage | Market Outperform (N/A) |
3.63 (0.19) |
-94.77% | Details | |
| 5/12/2020 | Halozyme Therapeutics | HALO | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/26/2020 | Vanda Pharmaceuticals | VNDA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/24/2020 | Esperion Therapeutics | ESPR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 2/3/2020 | Esperion Therapeutics | ESPR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/14/2020 | MorphoSys AG | MOR | Maintain | Market Outperform (N/A) |
|
Details | ||
| 1/9/2020 | Lennar | LEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/19/2019 | Minerva Neurosciences | NERV | Maintain | Market Outperform (N/A) |
|
Details | ||
| 12/9/2019 | argenx SE | ARGX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/26/2019 | Acadia Pharmaceuticals | ACAD | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/13/2019 | Intrexon | XON | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/23/2019 | Axovant Gene Therapies | AXGT | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/18/2019 | Syros Pharmaceuticals | SYRS | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/9/2019 | Rezolute | RZLT | New Coverage | Market Outperform (N/A) |
0.12 (3.11) |
2491.67% | Details | |
| 10/3/2019 | Lennar | LEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/26/2019 | Zogenix, Inc. | ZGNX | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/20/2019 | Gamida Cell Ltd. | GMDA | New Coverage | Market Outperform (N/A) |
4.38 (0.36) |
-91.78% | Details | |
| 9/13/2019 | Cytokinetics | CYTK | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/5/2019 | Zafgen | ZFGN | Downgrade | Market Perform (Market Outperform) |
0.82 (0.99) |
20.73% | Details | |
| 8/8/2019 | Intra-Cellular Therapies | ITCI | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/7/2019 | Intra-Cellular Therapies | ITCI | Maintain | Market Outperform (N/A) |
|
Details | ||
| 7/16/2019 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (N/A) |
|
Details | ||
| 6/25/2019 | Minerva Neurosciences | NERV | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 6/3/2019 | Cortexyme Inc. | CRTX | New Coverage | Market Outperform (N/A) |
26.65 (1.95) |
-92.68% | Details | |
| 4/4/2019 | Intrexon | XON | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/28/2019 | Proteon Therapeutics | PRTO | Downgrade | Market Perform (Market Outperform) |
3.48 (0.84) |
-75.86% | Details | |
| 3/28/2019 | Lennar | LEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/12/2019 | Zafgen | ZFGN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 3/8/2019 | Syros Pharmaceuticals | SYRS | New Coverage | Market Outperform (N/A) |
7.07 (3.23) |
-54.31% | Details | |
| 2/11/2019 | Proteon Therapeutics | PRTO | Upgrade | Market Outperform (Market Perform) |
2.76 (3.48) |
26.09% | Details | |
| 1/3/2019 | Aevi | GNMX | Downgrade | Market Perform (Market Outperform) |
0.70 (0.17) |
-75.71% | Details | |
| 12/6/2018 | Vanda Pharmaceuticals | VNDA | Maintain | Market Outperform (N/A) |
|
Details | ||
| 11/12/2018 | Neos Therapeutics | NEOS | Maintain | Market Outperform (Market Outperform) |
|
Details | ||
| 10/12/2018 | Trevena | TRVN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/10/2018 | Trevena | TRVN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/10/2018 | Intrexon | XON | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/9/2018 | Intrexon | XON | Maintain | Market Outperform (N/A) |
|
Details | ||
| 10/5/2018 | Lennar | LEN | Maintain | Market Outperform (N/A) |
|
Details | ||
| 9/4/2018 | Aquestive Therapeutics | AQST | Maintain | Market Outperform (N/A) |
|
Details | ||
| 8/20/2018 | Aquestive Therapeutics | AQST | New Coverage | Market Outperform (N/A) |
16.10 (4.22) |
-73.79% | Details |
